In the midst of the COVID-19 vaccines rollout, clinicians and researchers are working to assess next generation COVID-19 vaccine candidates, and as part of that effort, researchers are presenting alternatives to measure a vaccine’s effectiveness by using immune markers that a person develops in their blood after inoculation. Dan Barouch, MD, PhD (Center for Virology and Vaccine Research, BIDMC) spoke to how trials so far suggest that levels of an antibody called immunoglobulin G (IgG) could serve as that proxy indicator.
As placebo-controlled testing falls out of favour, vaccine developers eye blood markers and challenge trials to assess next-generation candidates.